Could a gorilla virus help beat HIV? new vaccine trial launches
NCT ID NCT06617091
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This Phase 1 trial is testing a new HIV vaccine called GRAdHIVNE1, made using a harmless gorilla virus to deliver HIV protein pieces. The study will enroll 120 healthy adults in southern Africa, some living with HIV and some without, to check safety and measure immune responses. Participants will receive either the vaccine or a placebo, and researchers will monitor for side effects and T-cell activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AHRI
RECRUITINGMtubatuba, KwaZulu-Natal, South Africa
-
DTHF
RECRUITINGCape Town, Western Cape, South Africa
-
Mutala
RECRUITINGHarare, Harare, Zimbabwe
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GRAdHIVNE1 vaccine (a gorilla adenovirus vector vaccine)
What this could lead to
If successful, this could pave the way for a preventive HIV vaccine that works in both HIV-negative and HIV-positive people.
What could go wrong
This is an early Phase 1 trial with only 120 participants, so it is primarily testing safety and immune response, not effectiveness. The vaccine may not produce strong or lasting immunity.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.